Prosecution Insights
Last updated: April 19, 2026

Tyk Medicines Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18568761 COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF BURKETT, DANIEL JOHN 1624 Non-Final OA Dec 08, 2023
18006493 COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF TOWNSLEY, SARA ELIZABETH 1629 Final Rejection Jan 23, 2023
17789115 COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF NOLAN, JASON MICHAEL 1623 Final Rejection Jun 24, 2022

Managing Tyk Medicines Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month